Vitiligo - Vîtilîgo
☆ Di encamên 2022-an de Stiftung Warentest ji Almanyayê, razîbûna xerîdar bi ModelDerm tenê ji şêwirmendên telemedicine drav hindik hindiktir bû.
Tedawiya vîtîligoya tiliyan ji deverên din dijwartir e. Ji bilî ku ji hêla kozmetîkî ve nebaş e, vitiligo normal e û ne vegirtî ye. Di dermatolojiyê de, tedawiya herî bi bandor fototerapî an jî tedawiya lazerê (excimer) 2-3 caran di hefteyê de herî kêm 1 sal e. Heke hûn ji ber sedemên aborî an ji ber ku hûn mijûl in nikaribin pir caran biçin nexweşxaneyê, hûn dikarin makîneyek fototerapî ya ku ji bo karanîna malê hatî pejirandin biceribînin.
Vitiligoya çavan
Vitiligo li dest
relevance score : -100.0%
ReferencesVitiligo nexweşiyek gelemperî ya çermê ye ku ji ber windabûna melanocytes sedema çermên spî dibe. Lêkolînên dawî nîşan dide ku ev nexweşî otîmmûn e. Her çend pir caran wekî pirsgirêkek kozmetîkî tê dîtin, ew dikare bi kûrahî bandorê li ser xweşbûna giyanî û jiyana rojane bike. Di sala 2011-an de, pisporê celebek bi navê segmental vitiligo ji yên din cuda dabeş kir.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Nexweşên vitiligo yên çalak gelek vebijarkên dermankirinê hene, wek glucocorticoids pergalî, fototerapî, û immunosuppressants pergalî. Nexweşên vitiligo yên stabîl dikarin ji kortikosteroidên herêmî, înhîbîtorên calcineurin-ê yên herêmî, fototerapî, û prosedurên veguheztinê rehetiyê bistînin. Pêşveçûnên dawî yên di têgihîştina pêvajoyên bingehîn ên vitiligo de rê li pêşkeftina dermanên armanckirî girtiye. Heya niha, înhîbîtorên JAK-ê yên herî sozdar in, ku tolerans û encamên fonksiyonel ên baş peyda dikin, tevî xetera çalakkirina enfeksiyonên nepenî û bandorên aliyî yên pergalî yên ku bi ajanên din ên immunosuppressive re hevpar in. Lêkolîna domdar armanc dike ku cytokinesên sereke yên ku di pêşkeftina vitiligo de beşdar in nas bikin (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF). Astengkirina van cytokines di modelên heywanan û di hin nexweşan de têkildar e. Wekî din, lêpirsînên li ser miRNA-based therapeutics û adoptive Treg cell therapy jî têne kirin.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Ji bo vîtîligoyê dermanek nîn e. Ji bo kesên ku çermê sivik, tav û makyaj hene, bi gelemperî têne pêşniyar kirin. Vebijarkên din ên dermankirinê dikarin kremên steroîdan an fototerapî bin.
○ Demankirinî
#Phototherapy
#Excimer laser
#Tacrolimus ointment